Rabeprazole resubmitted for GORD in Japan
This article was originally published in Scrip
Eisai has resubmitted an approval filing in Japan for its proton pump inhibitor Pariet (rabeprazole), for the additional indication of non-erosive gastro-oesophageal reflux disease (GORD/GERD).
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.